

REMARKS

Applicants submit herewith a full set of replacement sheets comprising twenty-seven sheets of drawings.

In response to the Notice, Figure 16 has been corrected for the discrepancy of the drawings with the specification. Figure 16 has been amended to label the top of the figure as “Fig. 16A” and the bottom of the figure as “Fig. 16B.”

Figure 3 has been divided into two separate sheets, with the top half of the Figure designated as Fig. 3A and the bottom half of the Figure designated as Fig. 3B.

Figure 6 has been divided into two separate sheets, with the top half of the Figure designated as Fig. 6A and the bottom half of the Figure designated as Fig. 6B.

Figure 7 has been divided into two separate sheets, with the top half of the Figure designated as Fig. 7A and the bottom half of the Figure designated as Fig. 7B.

Figure 11 has been divided into two separate sections, with the top half of the Figure designated as Fig. 11A and the bottom half of the Figure designated as Fig. 11B.

Figure 13 has been divided into three separate sheets, with the top and rightmost section of the Figure designated as Fig. 13A, the middle section of the Figure designated as Fig. 13B, and the bottom section designated as Fig. 13C.


In accordance with changes made to the drawings, Applicants have amended the Brief Description of the Drawings and the Detailed Description in the specification to refer to the changes in the figure designations, *e.g.*, from Figure 13 to Figures 13A-13C.

Applicants submit that there is no new matter added as a consequence of the amendments to the drawings or the specification.

The present submission is accompanied by the payment of the issue fee for the above-referenced application.

Applicants do not believe that any fee is required in connection with the submission of this document. However, should any fee be required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit any overpayments made, to Deposit Account 02-4377. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



Lisa B. Kole
PTO Reg. No. 35,225

Carmella L. Stephens
PTO Reg. No. 41,328

Attorneys for Applicants
BAKER BOTTS, L.L.P.
30 Rockefeller Plaza
New York, NY 10112
(212) 408-2500




FIG. 3A




FIG. 3B

FIGURE 3
 A31869 A
 (SHEET 3 OF 23)





FIGURE 6

A31869A

(SHEET 6 OF 23)




FIGURE 7


A31869 A

(SHEET 7 OF 23)



A31869 A

(SHEET 11 OF 23)



~~FIGURE 11~~

AUG 02 2004
 PATENT & TRADEMARK OFFICE

A31869A(sheet 13 of 23)

LEGEND FOR FIGS 13A, 13B, AND 13C

- ★ POZ/BTB domain
- Kelch repeat
- ⊙ ring finger domain
- ▨ fibronectin III domain
- ▤ cyclin repeat
- ▲ EGF-like domain
- ◉ CUB domain
- ▲ laminin EGF-like domain
- ↗ transmembrane helix
- BP - bipartite nuclear localization signal
- ▨ transverse domain
- ◉ new A-domain
- ▨ new POZ-linker domain
- ▨ new B-domain
- ◉ new SPOP domain
- ▨ new(?) TN (Tumor Necrosis) domain
- ◉ fos/jun DNA-binding domain
- ▨ gi11707204-domain
- ◉ new HAT domain (Hemagglutinin, Alpha toxin, Tumor necrosis-factor or alpha-induced protein)
- ◉ death domain
- ◉ kinase domain
- ▨ best repeat
- ◉ Zn-finger C₂H₂
- ▨ Proline-rich region
- ▨ PKC-C1 domain, GAG/PE-binding
- ▨ PKC-C2 domain
- ◉ protein kinase domain




Figure 13



A31860A
(Sheet 19 of 23)

Activated CD4⁺ T-cells

Rpt1 (represses expression of IL-2 receptor)




FIG. 16A

When rpt1 is knocked out:




FIG. 16B

~~Figure 16~~